双極性障害の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、流通チャネル別、地域別 - 産業予測、2025-2032年

双極性障害の世界市場規模は、2023年に53億6,000万米ドルと評価され、2024年の54億9,000万米ドルから2032年には66億4,000万米ドルに成長し、予測期間中（2025-2032年）にCAGR 2.4％で成長する見通しです。

現在双極性障害として知られる躁うつ病は、躁病エピソードとうつ病エピソードを含む極端な気分変動を特徴とします。この疾患には遺伝的素因が重要な役割を果たしており、単一の原因因子ではなく複数の遺伝子が関与しています。双極性障害には、主に双極性障害I、双極性障害II、周期性障害の3つのタイプがあります。興味深いことに、インドの双極性障害の生涯リスクはわずか0.1%だが、米国は4.4%とかなり高いです。双極性障害治療市場は、啓発キャンペーンの増加、正確な気分評価技術の進歩、発症率の上昇によって拡大しています。さらに、三環系抗うつ薬の使用は副作用のために減少しており、より効果的な治療オプションへのシフトにつながっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 顧客と購買基準の分析

双極性障害市場規模：タイプ別

• 市場概要
• 気分安定剤
• 抗けいれん薬
• 抗精神病薬
• 抗うつ薬
• 抗不安薬
• その他のタイプ

双極性障害市場規模：薬剤クラス別

• 市場概要
• 選択的セロトニン再取り込み阻害薬
• セロトニンノルエピネフリン再取り込み阻害剤
• 三環系抗うつ薬
• モノアミン酸化酵素阻害剤
• ベンゾジアゼピン
• ベータ遮断薬
• その他の薬物クラス

双極性障害市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

双極性障害市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Eli Lilly and Company（USA）
• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• AstraZeneca plc（UK）
• Otsuka Holdings Co., Ltd.（Japan）
• H. Lundbeck A/S（Denmark）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Novartis International AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• Alkermes plc（Ireland）
• Mylan N.V.（USA）
• Neurocrine Biosciences, Inc.（USA）
• Vanda Pharmaceuticals Inc.（USA）
• Sunovion Pharmaceuticals Inc.（USA）
• Intra-Cellular Therapies, Inc.（USA）
• Acadia Pharmaceuticals Inc.（USA）
• Reviva Pharmaceuticals Holdings, Inc.（USA）

結論と推奨事項

Global Bipolar Disorder Market size was valued at USD 5.36 billion in 2023 and is poised to grow from USD 5.49 billion in 2024 to USD 6.64 billion by 2032, growing at a CAGR of 2.4% during the forecast period (2025-2032).

Manic depression, now known as bipolar disorder, is characterized by extreme mood fluctuations, including manic and depressive episodes. Genetic predisposition plays a significant role in this condition, with multiple genes involved rather than a single causative factor. There are three main types of bipolar disorder: bipolar I, bipolar II, and cyclothymic disorder. Interestingly, while India's lifetime risk for bipolar disorder is just 0.1%, the United States has a significantly higher prevalence at 4.4%. The market for bipolar disorder treatment is expanding, driven by increasing awareness campaigns, advancements in technology for accurate mood assessment, and the rising incidence of the disorder. Additionally, the use of tricyclic antidepressants is declining due to their side effects, leading to a shift toward more effective treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bipolar Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bipolar Disorder Market Segmental Analysis

Global Bipolar Disorder Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Mood stabilizer, Anticonvulsants, Antipsychotic drugs, Antidepressant drugs, Antianxiety drugs and Other Types. Based on Drug Class, the market is segmented into Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor, Tricyclic antidepressant drugs, Monoamine oxidase inhibitors, Benzodiazepines, Beta blockers and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bipolar Disorder Market

The global bipolar disorder market is expected to witness significant growth driven by a strong focus on enhancing product offerings and an increasing prevalence of mental health issues. Key players in the industry are actively expanding their product portfolios, which includes the introduction and approval of new pharmaceuticals specifically targeting bipolar disorder. For instance, the FDA recently approved Allergan plc and Gedeon Richter plc's supplemental new drug application for VRAYLAR (cariprazine), underscoring the commitment to advancing treatment options. Furthermore, rising awareness initiatives and government efforts aimed at highlighting the impacts of bipolar disorder, alongside a growing demand for effective antidepressants, are contributing to a reduction in the overall burden of this mental health condition.

Restraints in the Global Bipolar Disorder Market

The Global Bipolar Disorder market faces significant challenges due to several restraints that could impede its growth. A prominent issue is the insufficient availability of effective medications and suitable treatment protocols, which complicates management of the condition. Additionally, the expiration of patents for major drugs, such as Latuda, Abilify Maintena, and Risperdal Consta, poses further limitations, potentially leading to increased competition from generic alternatives like lithium. Moreover, the absence of reliable diagnostic methods and the adverse side effects associated with existing treatments exacerbate these market constraints. However, advancements in drug combination therapies present potential avenues for future growth within this sector.

Market Trends of the Global Bipolar Disorder Market

The global bipolar disorder market is witnessing significant growth, driven by the rising prevalence of mental health disorders, particularly among children and adolescents. Increased awareness and reduced stigma surrounding mental illnesses have led to higher diagnosis rates of bipolar disorder, prompting a surge in demand for effective treatment options. Advances in pharmacotherapy and psychotherapy, combined with the integration of digital health solutions, are further transforming the therapeutic landscape. Additionally, greater emphasis on personalized medicine and early intervention strategies is anticipated to enhance patient outcomes, solidifying bipolar disorder as a critical area within the broader mental health market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Customer & Buying Criteria Analysis

Global Bipolar Disorder Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mood stabilizer
• Anticonvulsants
• Antipsychotic drugs
• Antidepressant drugs
• Antianxiety drugs
• Other Types

Global Bipolar Disorder Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Selective serotonin reuptake inhibitor
• Serotonin norepinephrine reuptake inhibitor
• Tricyclic antidepressant drugs
• Monoamine oxidase inhibitors
• Benzodiazepines
• Beta blockers
• Other Drug Classes

Global Bipolar Disorder Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Bipolar Disorder Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations